Therapeutic applications of mesenchymal stem cell-derived extracellular vesicles in pain management: A narrative review of emerging evidence and future directions

Published on March 11, 2026

World J Stem Cells. 2026 Feb 26;18(2):116184. doi: 10.4252/wjsc.v18.i2.116184.

ABSTRACT

Pain remains a major clinical challenge because current therapies often have limited efficacy and substantial adverse effects. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) are emerging as promising candidates with anti-inflammatory, immunomodulatory, and neuroprotective actions. Preclinical studies show that MSC-EVs alleviate inflammatory, neuropathic, and cancer-related pain by modulating immune responses and promoting neural repair, thereby reducing nociceptor sensitization. MSC-EVs also hold potential as drug-delivery vehicles and as biomarkers for pain diagnosis due to their stability and bioactive cargo (e.g., microRNAs and proteins). This narrative review summarizes terminology, mechanisms, therapeutic applications, and translational challenges of MSC-EVs in pain management, emphasizing their capacity to reshape the treatment landscape. Despite hurdles in scalable manufacturing, dosing, and regulation, ongoing clinical investigations support their promise as a biologically driven strategy for pain therapy.

PMID:41808887 | PMC:PMC12968799 | DOI:10.4252/wjsc.v18.i2.116184

Continue reading on website
Other news

Adenosine A(2A) receptors regulate D(2)-type medium spiny neurons in the nucleus accumbens to mediate pain and depression comorbidity

March 11, 2026
Front Pharmacol. 2026 Feb 23;17:1759544. doi: 10.3389/fphar.2026.1759544. eCollection 2026.ABSTRACTPersistent pathological pain often induces comorbid depressive-like symptoms, yet the underlying neuronal and molecular mechanisms remain unclear. The nucleus accumbens shell (NAcS) has been implicated in mediating pain sensation and emotional disorders, including depression. However, how it regulate

Regulatory, ethical, and clinical barriers to exosome use in interventional pain medicine

March 11, 2026
Interv Pain Med. 2026 Mar 3;5(1):100746. doi: 10.1016/j.inpm.2026.100746. eCollection 2026 Mar.ABSTRACTExosome-based therapies have drawn growing attention in interventional pain medicine as clinicians look for regenerative options beyond corticosteroids, radiofrequency ablation, and cell-based procedures. The early preclinical work suggests anti-inflammatory and neuromodulatory effects relevant t